At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
OPtimizing REperfusion by Intra-Arterial ThRomboLysis as Adjunct to Endovascular Treatment for Medium Vessel Occlusion (PEARL-MeVO): A Multicenter, Prospective, Randomized Controlled, Open-label, Blinded-Endpoint Clinical Trial
In Brief
A Phase 3 clinical trial evaluating Intra-arterial thrombolysis as adjunct to endovascular treatment and Standard medical treatment for Acute Ischemic Stroke. Currently recruiting, targeting 530 participants across 1 site.
Detailed Summary
PEARL-MeVO is an investigator-initiated, multicenter, prospective, randomized controlled, open-label, blinded endpoint (PROBE) clinical trial aiming at evaluating the efficacy and safety of intra-arterial thrombolysis as adjunct to endovascular treatment in improving 90-day functional outcome in acute ischemic stroke patients due to medium vessel occlusion (MeVO) within 24 hours of symptom onset.
Study Details
Timeline
Interventions
Intra-arterial thrombolysis as adjunct to endovascular treatment, in addition to standard medical treatment
Standard medical treatment